List of Excipients in Branded Drug LOMAIRA

Generic Drugs Containing LOMAIRA

Company	Ingredient	NDC	Excipient
KVK-TECH INC	phentermine hydrochloride	10702-001	CELLULOSE, MICROCRYSTALLINE
KVK-TECH INC	phentermine hydrochloride	10702-001	FD&C BLUE NO. 1
KVK-TECH INC	phentermine hydrochloride	10702-001	MAGNESIUM STEARATE
KVK-TECH INC	phentermine hydrochloride	10702-001	STARCH, CORN
KVK-TECH INC	phentermine hydrochloride	10702-001	STEARIC ACID
KVK-TECH INC	phentermine hydrochloride	10702-001	SUCROSE
Calvin Scott & Co Inc	phentermine hydrochloride	17224-840	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in LOMAIRA?

# Of NDCs	Excipient
1	BLUE 1
4	CELLULOSE, MICROCRYSTALLINE
3	FD&C BLUE NO. 1
4	MAGNESIUM STEARATE
4	STARCH, CORN
4	STEARIC ACID
4	SUCROSE

Lomaira Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Lomaira is an immediate-release, 8 mg phentermine hydrochloride tablet marketed by KVK-Tech for short-term weight management in adults, alongside caloric restriction and behavioral modification. Its commercial opportunity is based on dose flexibility, tablet convenience, and differentiation from higher-strength phentermine products rather than on a novel active ingredient or complex delivery system. The core excipient strategy is a conventional, low-cost immediate-release platform using lactose, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, and a colorant.[1]

The main commercial opportunities are generic-equivalent development, lactose-free reformulation, orally disintegrating or chewable dosage forms, unit-dose packaging, and combination products that improve adherence or reduce abuse risk. Any development program must account for phentermine's Schedule IV controlled-substance status, short-term FDA labeling, cardiovascular contraindications, and the potential for generic substitution.

What is Lomaira and how does its formulation work?

Lomaira contains phentermine hydrochloride equivalent to 8 mg of phentermine per tablet. The product is intended for oral administration up to three times daily, approximately 30 minutes before meals. It is a low-dose immediate-release product, unlike commonly marketed 15 mg, 30 mg, and 37.5 mg phentermine formulations.[1]

Lomaira formulation profile

Attribute	Lomaira profile
Active ingredient	Phentermine hydrochloride
Strength	8 mg
Dosage form	Immediate-release tablet
Route	Oral
FDA pathway	New drug application, 505(b)(2) framework
Indication	Short-term adjunct for weight reduction
Manufacturer	KVK-Tech, Inc.
Controlled substance	Schedule IV
Administration	Up to three times daily, about 30 minutes before meals
Key formulation objective	Rapid disintegration and immediate release

The active dose is small relative to total tablet mass. That gives the excipient system a major role in tablet manufacturability, content uniformity, disintegration, taste, color, and patient acceptability.

What excipients are used in Lomaira tablets?

Lomaira's inactive ingredients are lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, and FD&C Blue No. 1.[1]

Functional role of each excipient

Excipient	Primary function	Commercial and technical relevance
Lactose monohydrate	Diluent and tablet filler	Low cost, established regulatory history, but limits lactose-free positioning
Microcrystalline cellulose	Diluent and dry binder	Supports compactability and tablet robustness
Pregelatinized starch	Binder and disintegration aid	Improves granule strength and water uptake
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and immediate release
Magnesium stearate	Lubricant	Reduces ejection force but can delay wetting if overused
FD&C Blue No. 1	Colorant	Supports product identification and brand recognition

The formulation is commercially efficient. It uses widely available compendial excipients, avoids a complex modified-release system, and does not require specialized manufacturing equipment. The principal formulation risk is not chemical complexity. It is control of low-dose drug distribution, lubricant impact, tablet hardness, disintegration, and dissolution.

How strong is the excipient strategy for Lomaira?

The excipient strategy is strong for cost-efficient immediate-release manufacturing but limited as a source of durable differentiation. Standard excipients make the product relatively easy to reproduce. A competing developer could likely build a bioequivalent 8 mg immediate-release tablet using the same or equivalent excipients.

The most important technical issue is content uniformity. Phentermine hydrochloride represents a relatively small fraction of total tablet weight. Manufacturing controls must ensure uniform drug distribution through blending, granulation or direct compression, and tablet weight control.

Key formulation performance attributes

A competing product would need to control:

1. Assay and content uniformity at the 8 mg strength.
2. Tablet friability and mechanical strength.
3. Disintegration time.
4. Dissolution across relevant pH conditions.
5. Moisture sensitivity.
6. Lubrication level and mixing time.
7. Color consistency and visual identification.
8. Stability under commercial packaging conditions.

The presence of croscarmellose sodium and pregelatinized starch supports immediate release. Excessive magnesium stearate or over-lubrication could reduce wettability and slow dissolution. Lactose and starch also require control of moisture exposure during processing and storage.

What formulations are protected or commercially differentiated by Lomaira?

Lomaira's commercial differentiation is based primarily on its 8 mg strength and dosing flexibility. The label permits patients to use lower individual doses than conventional 30 mg or 37.5 mg tablets. This can be relevant for patients requiring titration, lower stimulant exposure, or divided dosing.

The core immediate-release tablet is not a technically complex delivery system. Its differentiating attributes are:

• Low unit strength.
• Small, portable tablet.
• Divided-dose administration.
• Brand-specific blue color.
• Established phentermine labeling.
• Potential use in patients who do not tolerate higher-strength tablets.

Potential follow-on formulation concepts include:

Lactose-free tablets

Replacing lactose with mannitol, anhydrous dibasic calcium phosphate, or additional microcrystalline cellulose could address lactose intolerance and create a formulation distinction. The replacement must preserve hardness, disintegration, dissolution, and content uniformity.

Mannitol could improve mouthfeel and support chewable or orally disintegrating formats. It may require careful control of compression force and hygroscopicity. Dibasic calcium phosphate can improve tablet strength but may alter dissolution behavior and compatibility with the active ingredient.

Orally disintegrating tablets

An orally disintegrating phentermine product could reduce the need for water and support discreet administration. The main challenges are bitterness, dose uniformity, friability, and control of rapid disintegration without excessive moisture sensitivity.

Taste-masking options include ion-exchange resins, polymer coating, lipid-based barriers, and sweetener-flavor systems. Any taste-masked product would require dissolution testing to demonstrate that the barrier does not delay or alter immediate release.

Chewable tablets

A chewable 8 mg tablet could provide a patient-convenience advantage. Mannitol, xylitol, crospovidone, flavors, and high-intensity sweeteners are potential excipient components. The product would need clear labeling to prevent accidental administration by children and to address the controlled-substance risk.

Scored or multi-strength tablets

A scored 16 mg tablet could theoretically provide half-tablet dosing, but the approach would have to address dose uniformity after splitting and FDA expectations for tablet scoring. A multi-strength line, such as 4 mg, 8 mg, and 16 mg, could create a titration platform but would expand manufacturing and regulatory requirements.

Unit-dose packaging

Blister packaging could improve dose tracking, portability, and diversion controls. Calendar packs or time-of-day packaging could support the three-times-daily dosing schedule. Packaging does not generally create formulation patent value, but it can produce commercial differentiation and support adherence programs.

What FDA regulatory issues affect Lomaira formulation development?

Lomaira is regulated as a prescription drug containing a Schedule IV controlled substance. A follow-on product must address both ordinary oral solid dosage requirements and controlled-substance controls.

FDA considerations

A generic or alternative formulation may need to demonstrate:

• Pharmaceutical equivalence where applicable.
• Bioequivalence under the relevant FDA pathway.
• Comparable immediate-release performance.
• Adequate stability and impurity control.
• Manufacturing controls for a low-dose tablet.
• Abuse, diversion, and inventory controls.
• Appropriate labeling for short-term use and contraindications.

The FDA label identifies important contraindications, including cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, and use with monoamine oxidase inhibitors within 14 days.[1] Formulation changes cannot alter the product's risk communication or create an impression that the drug is appropriate for chronic obesity treatment.

Lomaira is not a biologic. Biosimilar pathways, interchangeability standards for biologics, and biologic manufacturing barriers do not apply. Competitive entry is principally a small-molecule generic or 505(b)(2) issue.

What is the Orange Book status of Lomaira?

The Orange Book is the relevant source for FDA-listed patents, exclusivity, therapeutic equivalence codes, and reference-product information.[2] Lomaira's competitive position should be evaluated against the current Orange Book entry for its NDA and against approved abbreviated new drug applications for phentermine hydrochloride products.

A key distinction is between:

• The branded Lomaira NDA.
• Older phentermine hydrochloride products.
• Generic products with different strengths.
• Products that may be therapeutically equivalent but do not replicate the 8 mg strength.
• Any listed patents or regulatory exclusivities tied specifically to Lomaira.

The active ingredient is old and widely genericized. That reduces the likelihood that the active pharmaceutical ingredient itself creates a durable barrier. Any defensible exclusivity would more likely arise from a listed formulation, method-of-use claim, regulatory exclusivity period, or practical market advantage in the 8 mg strength.

When does Lomaira lose exclusivity and what generic entry risks exist?

The economic risk to Lomaira comes from substitution by existing phentermine products as well as from a new 8 mg generic. A generic does not always need to replicate the brand's entire commercial proposition. It can compete on price if it satisfies FDA requirements and receives an appropriate therapeutic-equivalence designation.

Generic launch scenarios

Scenario	Commercial effect
Existing higher-strength phentermine products remain available	Physicians may prescribe dose splitting or alternative strengths
8 mg generic launches	Direct price pressure and pharmacy substitution
Lactose-free or ODT competitor launches	Brand differentiation weakens in sensitive patient segments
Multiple generic entrants launch	Net pricing declines and formulary leverage shifts to purchasers
Brand retains prescriber loyalty	Lomaira may preserve a niche despite generic availability
Controlled-substance distribution constraints tighten	Supply reliability and wholesaler controls become more important

A Paragraph IV challenge would target any unexpired Orange Book-listed patent associated with Lomaira. The commercial significance would depend on the patent's claims, statutory expiration, pediatric exclusivity, and the timing of FDA approval. A Paragraph IV filing could create litigation even if the underlying formulation is commercially straightforward.

No reliable business conclusion should treat the active ingredient's age as proof that no patent barrier exists. The relevant analysis is patent-by-patent and must distinguish composition, formulation, method-of-use, and packaging claims.

What patents protect Lomaira?

The principal patent questions concern whether the FDA Orange Book lists any unexpired patents for the Lomaira NDA and whether those patents cover:

• The 8 mg tablet composition.
• Immediate-release performance.
• Specific excipient combinations.
• Low-dose phentermine administration.
• Weight-management methods.
• Tablet scoring or packaging.

A method-of-use patent would face practical enforcement limits if generic labeling omits the patented use, although induced-infringement and labeling disputes can still arise. A formulation patent would be more commercially relevant if it claims a narrow excipient ratio or measurable dissolution profile that a generic must avoid.

Patent strength is strongest where claims are tied to a reproducible product characteristic and where design-around options are limited. It is weaker where a competitor can substitute standard diluents, binders, or disintegrants without changing bioequivalence.

Which companies compete with Lomaira?

The competitive field includes KVK-Tech's Lomaira, generic phentermine hydrochloride manufacturers, and branded or generic products containing higher strengths of phentermine. The broader anti-obesity market includes GLP-1 receptor agonists and other chronic weight-management therapies, but those products do not compete on identical formulation or regulatory terms.

Competitive comparison

Product category	Dose flexibility	Chronic-use positioning	Formulation complexity	Main competitive advantage
Lomaira 8 mg	High	Limited by labeling	Low	Low-dose divided administration
Generic phentermine tablets	Variable	Generally short-term labeling	Low	Price
Higher-strength phentermine	Moderate	Limited by labeling	Low	Lower pill burden
GLP-1 receptor agonists	Product-specific	Chronic-use positioning	High	Different efficacy and treatment model
Combination obesity therapies	Product-specific	Chronic-use positioning	Moderate to high	Multi-mechanism treatment

Lomaira's most defensible commercial segment is patients and prescribers who value low-dose titration and divided administration. Its weakest segment is price-sensitive pharmacy volume where conventional phentermine products are acceptable substitutes.

What licensing and partnership opportunities exist for Lomaira excipients?

The most plausible licensing opportunities are formulation and platform partnerships rather than active-ingredient licensing. Potential partners include:

• Excipient suppliers with direct-compression platforms.
• Oral disintegration technology companies.
• Taste-masking specialists.
• Contract development and manufacturing organizations.
• Controlled-substance packaging and serialization providers.
• Telehealth and obesity-care companies.
• Generic manufacturers seeking an 8 mg product.

A reformulation partnership could target a lactose-free tablet, ODT, chewable tablet, or adherence-oriented blister pack. The commercial value would depend on whether the new product receives separate regulatory protection, earns a distinct reimbursement position, or captures patients who do not use the current tablet.

What manufacturing and intellectual-property barriers affect Lomaira?

Manufacturing barriers are moderate rather than high. Standard tablet equipment is sufficient, and the excipients are widely available. The more significant barriers are regulatory execution, controlled-substance compliance, reliable low-dose blending, and commercial access to pharmacies and prescribers.

The strongest practical barriers may include:

• FDA approval and bioequivalence requirements.
• Controlled-substance quotas and distribution controls.
• Product liability and pharmacovigilance.
• State-level controlled-substance rules.
• Wholesaler and pharmacy contracting.
• Brand recognition in obesity treatment.
• Differentiation from inexpensive generic phentermine.
• Protection of any active Orange Book-listed claims.

Geographic expansion outside the United States would require country-specific review of phentermine's controlled-substance status, approved indications, labeling, excipient restrictions, and local patent rights. A lactose-free or colorant-free reformulation may simplify access in markets with different excipient labeling expectations, but it would not eliminate local regulatory requirements.

What is the revenue exposure for Lomaira?

Revenue exposure is concentrated in the 8 mg niche and is vulnerable to generic substitution. A direct 8 mg generic would create the greatest price risk. Existing higher-strength phentermine products create indirect risk because prescribers can use alternative strengths when clinically appropriate.

Potential revenue levers include:

1. Maintaining reliable supply of the 8 mg strength.
2. Expanding pharmacy and telehealth distribution.
3. Introducing lactose-free or ODT formats.
4. Using blister packs to support adherence.
5. Building a broader low-dose strength portfolio.
6. Establishing authorized-generic or co-marketing arrangements.
7. Protecting any formulation or method-of-use claims before launch.

The value of a new excipient strategy will be highest where it solves a recognized patient problem. Replacing lactose alone may create a limited niche. An ODT or taste-masked product could create stronger differentiation but would carry higher development and stability costs.

Key Takeaways

• Lomaira is an 8 mg immediate-release phentermine hydrochloride tablet marketed by KVK-Tech.
• Its excipient system is conventional: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, and FD&C Blue No. 1.
• The principal technical challenge is low-dose content uniformity combined with rapid disintegration and dissolution.
• The strongest follow-on opportunities are lactose-free, orally disintegrating, chewable, and adherence-oriented packaged products.
• Generic risk is high because phentermine is an established small-molecule product with widely available generic strengths.
• Patent and exclusivity conclusions depend on the current Orange Book record and must be assessed by claim category.
• Biosimilar competition is irrelevant because Lomaira is a small-molecule tablet, not a biologic.
• Commercial differentiation depends more on dose flexibility, patient convenience, supply reliability, and channel access than on complex excipient technology.

FAQs

Can Lomaira be reformulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent. The reformulated product would need to maintain content uniformity, hardness, disintegration, dissolution, stability, and bioequivalence requirements.

Is an orally disintegrating Lomaira product commercially attractive?

Potentially. An ODT could improve convenience and create a differentiated product, but taste masking, friability, moisture protection, and controlled-substance packaging would raise development and manufacturing costs.

Does Lomaira have biosimilar competition?

No. Lomaira contains the small molecule phentermine hydrochloride. Competition would come from generic tablets or alternative 505(b)(2) formulations, not biosimilars.

What excipient has the greatest impact on Lomaira dissolution?

Croscarmellose sodium is the primary rapid-disintegration excipient, while magnesium stearate concentration and mixing time can materially affect wetting and dissolution. The combined system, rather than one ingredient alone, determines release performance.

Could a 4 mg or 16 mg Lomaira strength create a new commercial franchise?

Yes. A broader strength portfolio could support dose titration and reduce switching to competing phentermine products. The developer would still need to address FDA approval, content uniformity, tablet splitting where relevant, controlled-substance controls, and market demand.

References

1. U.S. Food and Drug Administration. (n.d.). Lomaira (phentermine hydrochloride) tablets, prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.